China’s National Medical Products Administration has granted a conditional approval for Merck’s COVID-19 treatment Molnupiravir, Reuters reports, citing the agency. The drug is approved for use in adult patients with mild to medium COVID infection and a high risk of progressing to severe cases, the report states. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- MRK Slips Despite New Chinese Approval
- Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks
- Merck and Kelun Biotech sign license and collaboration agreement in cancer
- Top 10 Dividend Growth Stocks and How to Choose Them
- AstraZeneca’s Lynparza approved in E.U. as first line treatment in mCRPC